ANDA 209601, held by Apotex. Teriflunomide.
As of Nov 16, 2026, ANDA 209601 (Teriflunomide), held by Apotex, was first approved by FDA on Nov 2, 2018, with 5 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 2, 2018 | Original application | Approved | None posted |
| Teriflunomide7MG · tablet;oral | Teriflunomide | Discontinued |
| Teriflunomide14MG · tablet;oral | Teriflunomide | Discontinued |
| Jan 29, 2025 | Supplement 7Labeling · Standard review | Approved | None posted |
| Dec 22, 2021 | Supplement 3Labeling · Standard review | Approved | None posted |
| Dec 22, 2021 | Supplement 4Labeling · Standard review | Approved | None posted |
| Jul 18, 2020 | Supplement 1Labeling · Standard review | Approved | None posted |
| Jul 18, 2020 | Supplement 2Labeling · Standard review | Approved | None posted |
| Nov 2, 2018 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters